companiesCompany
Optellum
Oxford company with the first FDA-cleared AI for judging whether a lung nodule on CT is likely to be cancer.
Overview
Optellum's Virtual Nodule Clinic (FDA 510(k) 2021, CE-marked) combines a deep-learning Lung Cancer Prediction score with nodule management software, used in NHS trusts and US health systems and in partnership with Johnson & Johnson's lung cancer initiative.
Headquarters
Oxford, GB
Scorecard
All companies#164of 680 companies, score 10
- approved products +6
- modalities +2
- regions +2
1 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Type
ai software
Website
Founded
2016
Pages like this
not linked directly; found by shared links- PersonWeimin Li
Shares Low-dose CT lung screening, AI in radiology, Non-small-cell lung cancer.
- PersonLecia V. Sequist
Shares Low-dose CT lung screening, AI in radiology, Non-small-cell lung cancer.
- TechnologySybil (MIT/MGH lung cancer risk from CT)
Shares Optellum Virtual Nodule Clinic, AI in radiology, Non-small-cell lung cancer.
- TechnologyNHS Targeted Lung Health Check (lung cancer screening programme)
Shares Low-dose CT lung screening, AI in radiology, Non-small-cell lung cancer.
- IdeaRequire stage-shift or interval-cancer endpoints for AI in cancer screening
- IdeaAI malignancy scores to end repeat scans and biopsies for benign lung nodules
- PersonRegina Barzilay
- InstitutionMUSC Hollings Cancer Center
Shares Low-dose CT lung screening, Non-small-cell lung cancer.